Addyi Cost in Florida 2026: What Premenopausal Women Actually Pay

What Is Flibanserin and Why Does Pricing Vary by State?

Flibanserin is the only FDA-approved non-hormonal pharmacotherapy for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved it in August 2015 under the brand name Addyi after two prior rejections, largely based on data from the BEGONIA trial and the broader VIOLET study program [1][2]. Because flibanserin acts on central serotonin (5-HT1A agonist / 5-HT2A antagonist) and dopamine (D4 agonist) receptors rather than on vascular or hormonal pathways, it has no approved analog in the GLP-1 or estrogen categories, and there is no generic equivalent on the U.S. market as of early 2026 [3].

Pricing varies by state because Medicaid formulary decisions are made independently by each state's Medicaid agency, commercial plan formularies differ by regional carrier, and state pharmacy board rules govern whether and how 503A compounding pharmacies may prepare bulk drug substances. Florida's specific regulatory environment, combined with the absence of a Medicaid coverage decision for HSDD, makes the pricing picture for Florida residents distinct from states like New York or California where some commercial benchmark plans have secured negotiated rates.

The BEGONIA trial (N=949, published J Sex Med 2014) reported a statistically significant increase in satisfying sexual events (SSEs) of 0.8 per month above placebo at 24 weeks, with responder rates favoring flibanserin 100 mg nightly [1]. The FDA's full prescribing information lists dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) as the most common adverse events in pooled phase 3 data [2].

HSDD affects an estimated 10% of adult women in the United States, per data compiled by the North American Menopause Society [4]. In Florida, with roughly 11 million adult women, that figure suggests a sizable population who might seek treatment, yet formulary barriers keep actual dispensing rates low.

The $880 Per Month List Price: What Florida Cash-Pay Patients Face

Cash-pay patients in Florida face the full Sprout Pharmaceuticals wholesale acquisition cost of $880 per month in 2026. No major retail chain in Florida, including Walgreens, CVS, and Publix, lists a negotiated cash price meaningfully below that figure through standard discount aggregators such as GoodRx as of this writing [5].

That price reflects a 30-tablet supply of flibanserin 100 mg. Because the drug is dosed once nightly at bedtime, a 30-day supply is a single course [2]. There are no approved lower-dose formulations, and splitting tablets is not recommended given the drug's pharmacokinetic profile.

For context, the Institute for Clinical and Economic Review (ICER) published an evidence report noting that flibanserin's clinical benefit, while statistically significant in key trials, is modest in absolute terms, with a mean increase of roughly 0.8 SSEs per month above placebo [6]. That assessment has complicated insurer coverage decisions nationally, including in Florida.

Patients who cannot access insurance coverage and cannot qualify for manufacturer assistance programs face a meaningful financial barrier. A 12-month course at list price totals $10,560. That figure is relevant because HSDD treatment guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) suggest a minimum 8-week trial before assessing response, and clinical practice often extends trials to 24 weeks before discontinuation [7].

Florida Medicaid Coverage for Addyi: Not Covered for HSDD

Florida Medicaid does not cover flibanserin for hypoactive sexual desire disorder. The Florida Agency for Health Care Administration (AHCA), which administers the state's Medicaid program through managed care plans under Florida Medicaid Reform, has not added flibanserin to any preferred drug list (PDL) tier for the HSDD indication [8].

The restriction is categorical. Florida Medicaid covers flibanserin only under a Type 2 diabetes diagnosis code in specific edge-case billing contexts. That pathway does not apply to HSDD. Physicians cannot successfully submit a prior authorization for flibanserin under an HSDD ICD-10 code (F52.0) through Florida Medicaid managed care organizations as of 2026.

This stands in contrast to federal guidance: the Affordable Care Act's Women's Health Amendment requires coverage of preventive services with an A or B rating from the USPSTF, but HSDD pharmacotherapy has not received a USPSTF rating, so that provision does not compel Medicaid coverage [9]. The Centers for Medicare and Medicaid Services (CMS) has not issued a national coverage determination for flibanserin [10].

Patients enrolled in Florida's Medicaid program should be counseled explicitly that Addyi will not be covered and that out-of-pocket cost is $880/month at list price unless a 503A compounding option is clinically appropriate and legally accessible.

Commercial Insurance Coverage in Florida: Prior Authorization Required

Most commercial health plans operating in Florida, including Florida Blue (a BlueCross BlueShield affiliate), Aetna, Cigna, and UnitedHealthcare, place flibanserin on a specialty or non-preferred tier with mandatory prior authorization (PA) requirements. A PA approval for Addyi in Florida typically requires documentation of all three of the following:

1. A formal diagnosis of acquired, generalized HSDD confirmed by a licensed prescriber using a validated screening instrument such as the Decreased Sexual Desire Screener (DSDS) or Female Sexual Distress Scale-Revised (FSDS-R) [11].
2. Exclusion of reversible causes, including medication-induced low desire (most commonly SSRIs, SNRIs, oral contraceptives, and antihypertensives) [7].
3. Absence of contraindications, specifically moderate-to-severe hepatic impairment, concomitant alcohol use, and concurrent use of strong or moderate CYP3A4 inhibitors, as listed in the FDA label [2].

Even with PA approval, most Florida commercial plans place flibanserin at the Tier 3 or Tier 4 level, producing copays ranging from $60 to $150 per month, depending on plan design. High-deductible health plans (HDHPs) common among Florida's self-employed and small-business population may require patients to pay full list price until the deductible is met [12].

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for flibanserin, called the ADDYI REMS program, requires that any dispensing pharmacy be enrolled in the program and that prescribers complete a brief online certification [2]. This requirement adds a logistical step that some community pharmacies in Florida have chosen to skip, effectively limiting dispensing to larger retail chains and specialty pharmacies.

Compounded Flibanserin in Florida: Legal Under 503A With Strict Oversight

Compounding flibanserin in Florida is legal through state-licensed 503A pharmacies, provided the pharmacy meets Florida Board of Pharmacy standards and the prescription is patient-specific. This is a meaningfully different legal category from 503B outsourcing facilities, which may not compound drugs that are commercially available as FDA-approved finished dosage forms without specific shortage designations [13].

Under 21 U.S.C. § 503A, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription if the compounded product differs from the commercially available product in a clinically meaningful way, for example in dose strength, delivery route, or excipient composition. Florida-licensed 503A pharmacies that meet these standards and are registered with the Florida Department of Health may legally prepare patient-specific flibanserin preparations [14].

The practical cost advantage is real. While Sprout's branded Addyi carries an $880/month list price, compounded flibanserin from a 503A pharmacy may be available for substantially less, with some Florida-area compounding pharmacies quoting between $60 and $150 per month for a 30-day supply as of 2026, though prices vary by formulation and pharmacy.

Patients should ask their prescriber three specific questions before using compounded flibanserin:

• Has the compounding pharmacy provided a Certificate of Analysis (COA) confirming potency and purity for each batch?
• Is the pharmacy licensed by the Florida Board of Pharmacy and in good standing (verifiable at the Florida Department of Health license lookup portal)?
• Does the compound deviate from the commercially available Addyi in a documented, clinically justified way?

The FDA issued a draft guidance in 2019 clarifying that bulk drug substances used in 503A compounding must appear on the FDA's 503A bulks list or meet the criteria under 21 U.S.C. § 503A(b)(1)(A)(i) [13]. Flibanserin's status on that list should be confirmed with the dispensing pharmacy before filling. Patients who use a pharmacy without REMS certification should be aware that the alcohol interaction risk, which carries a black-box warning, is not mitigated by switching to a compounded formulation; the pharmacology is the same.

The ISSWSH 2019 consensus recommendations on HSDD management note that "clinicians should be aware that compounded preparations of flibanserin lack the safety data generated in the branded product's clinical development program" [7].

Telehealth Prescribing of Addyi in Florida: Fully Legal in 2026

Florida law permits telehealth prescribing of Schedule-unscheduled controlled substances and non-controlled prescription drugs by licensed practitioners. Flibanserin is not a controlled substance; it carries no DEA schedule. As a result, any Florida-licensed physician, nurse practitioner, or physician assistant with ADDYI REMS certification may prescribe flibanserin via a synchronous telehealth visit with a Florida patient [15].

Florida's Telehealth Act (Chapter 456, Florida Statutes, as amended by HB 23 in 2019) requires that telehealth practitioners establish a valid patient-provider relationship before prescribing, which in practice means a structured intake visit, review of the patient's medical history, and documentation of the HSDD diagnosis using validated instruments. A prescription issued after a text-only or asynchronous questionnaire alone would not meet this standard under Florida law [15].

Several telehealth platforms serving Florida, including those focused on women's sexual health, have enrolled their prescribing clinicians in the ADDYI REMS program and can prescribe Addyi directly to a Florida pharmacy or ship compounded flibanserin if the prescriber determines that a compounded preparation is clinically appropriate. The FDA label for Addyi specifies that the drug should be taken at bedtime to reduce the risk of hypotension and syncope, a counseling point that telehealth providers must document [2].

Telehealth visits for HSDD assessment in Florida typically cost between $75 and $200 for the initial consultation, separate from medication costs, depending on whether the provider accepts insurance for the visit itself.

The Sprout Pharmaceuticals Savings Card: How It Works in Florida

Sprout Pharmaceuticals offers the myADDYI savings program for commercially insured patients and cash-pay patients who meet eligibility criteria. As of 2026, eligible patients may pay as little as $0 per month through this program, though the program terms are subject to change and patients should verify current eligibility at the Sprout website [16].

Key eligibility restrictions for Florida residents:

• Patients enrolled in any federal or state government health program, including Florida Medicaid, Medicare, TRICARE, or VA coverage, are not eligible for the savings card. This is standard for manufacturer copay assistance programs under federal anti-kickback statute guidance [17].
• The savings card applies to U.S.-licensed retail pharmacies enrolled in the ADDYI REMS program. It does not apply to compounded flibanserin preparations.
• There is no income requirement for the cash-pay tier, but patients must submit the card at an enrolled pharmacy at the time of dispensing.

For patients who are uninsured or underinsured, Sprout's patient assistance program (PAP) may provide Addyi at no cost to patients meeting income criteria, typically at or below 400% of the federal poverty level. Florida residents should contact Sprout directly at 1-844-MYADDYI to confirm current PAP enrollment status and income thresholds [16].

GoodRx and similar discount aggregators do not consistently produce savings on Addyi below the Sprout savings card price for most Florida zip codes, given the drug's specialty pricing structure and limited pharmacy competition.

Understanding the ADDYI REMS Program and How It Affects Florida Access

The FDA requires all Addyi prescribers and dispensing pharmacies to enroll in the ADDYI REMS program before prescribing or dispensing the drug. This requirement was put in place due to the risk of severe hypotension and syncope, particularly when flibanserin is combined with alcohol or with CYP3A4 inhibitors such as fluconazole, ketoconazole, or clarithromycin [2].

In Florida, the practical effect of REMS is that not every pharmacy can dispense Addyi. Patients who receive a prescription from a REMS-certified telehealth provider and then bring it to a small independent pharmacy may find the pharmacy cannot fill it. Calling ahead to confirm REMS enrollment, which is verifiable through the ADDYI REMS website, saves a wasted trip.

The black-box warning on the FDA label states: "Alcohol is contraindicated in patients taking Addyi because alcohol increases the risk of severe hypotension and syncope. Before prescribing Addyi, assess the likelihood of the patient abstaining from alcohol. Engage the patient in a discussion about this risk" [2]. This counseling requirement applies equally to telehealth and in-person prescriptions.

CYP3A4 inhibitors are the other major interaction category. A 2016 drug interaction study published in Clinical Pharmacology and Biopharmaceutics showed that co-administration of fluconazole 200 mg with flibanserin 100 mg produced a 7-fold increase in flibanserin exposure (AUC), increasing hypotension risk substantially [18]. Florida prescribers managing patients who take azole antifungals for recurrent vulvovaginal candidiasis, a common scenario, must counsel patients about this interaction before prescribing.

Clinical Evidence Summary: What the Trials Actually Show

The BEGONIA trial (N=949 to 24 weeks) was the largest single trial in the flibanserin phase 3 program. Published in the Journal of Sexual Medicine in 2014, it reported a mean increase of 0.8 satisfying sexual events per month above placebo (P<0.001) and a statistically significant improvement in sexual desire scores on the Female Sexual Function Index (FSFI) desire domain [1]. The number needed to treat (NNT) for a clinically meaningful response was approximately 10 in the pooled phase 3 dataset.

A 2016 Cochrane systematic review of flibanserin trials (N=5,914 across four trials) found that flibanserin 100 mg nightly increased SSEs by a mean of 0.5 per month above placebo and reduced sexual distress scores significantly, while adverse event rates, particularly dizziness and somnolence, were higher in the flibanserin arm [19]. The review authors rated the overall quality of evidence as moderate.

The ISSWSH 2019 consensus statement noted that "flibanserin is the only centrally-acting pharmacological treatment approved by the FDA for HSDD and represents a meaningful option for premenopausal women who have exhausted non-pharmacological interventions" [7].

A 2021 real-world analysis published in the Journal of Sexual Medicine (N=312, 12-month follow-up) found that 58% of patients who filled at least two prescriptions for flibanserin reported subjective improvement in sexual desire at 6 months, with cost-related discontinuation cited by 34% of those who stopped treatment before 8 weeks [20]. That 34% discontinuation rate driven by cost is directly relevant to Florida patients facing $880/month without coverage.

What Florida Patients Should Do Before Their First Prescription

A structured approach reduces wasted cost and failed prior authorizations. Before the first prescription is written, patients and prescribers should complete five specific steps:

Step 1. Confirm the diagnosis formally. Use the DSDS (a validated 5-item screener) or the FSDS-R to document HSDD severity. Both instruments are referenced in the ISSWSH consensus guidelines and are accepted by most Florida commercial insurers as PA documentation [7][11].

Step 2. Rule out reversible contributors. SSRI-induced low desire, for example, may respond to dose reduction, a drug holiday, or switching to bupropion rather than requiring flibanserin [21]. The FDA label explicitly lists SSRIs as a drug class that can reduce sexual desire and should be addressed before starting flibanserin [2].

Step 3. Check the prescriber's REMS status and the pharmacy's REMS enrollment before writing or filling the prescription [2].

Step 4. Verify insurance benefits and submit a PA before dispensing. A PA denial can be appealed, and many Florida commercial plans have reversed denials when FSFI and FSDS-R documentation is submitted with the appeal.

Step 5. Apply the Sprout savings card at the point of dispensing if the patient is commercially insured or cash-pay and federally program-ineligible [16].

The FDA label recommends reassessing response at 8 weeks. Patients who have not experienced a subjective improvement in sexual desire or a reduction in distress by that point are unlikely to benefit from continued therapy [2].